Brief: Hugel Receives US FDA Approval For Its Neurotoxin Letybo
March 4 (Reuters) - Hugel Inc 145020.KQ :
* HUGEL RECEIVES FDA APPROVAL IN THE UNITED STATES OF LETYBO
(LETIBOTULINUMTOXINA-WLBG) FOR INJECTION FOR THE TREATMENT OF
GLABELLAR LINES
* HUGEL INC: PLANS TO ACCELERATE TRANSITION FOR APPROVED
MEDICAL
USE WITH GOAL OF LAUNCHING TO AESTHETIC CLINICIANS IN BACK HALF
2024
Source text for Eikon: ID:nPn1B48Yga
Further company coverage: 145020.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hugel
See all newsBrief: Hugel To Cancel 54 Billion Won Worth Of Own Shares
Brief: Hugel Q3 Operating Profit 18 Billion Won, Down 62% From Year Earlier
Brief: Hugel Reports Q2 2026 Net Sales Up 25.1% TO KRW 137.90 Billion
Brief: Hugel Q4 Operating Profit 58.6 Billion Won, Up 26% From Year Earlier
Brief: Hugel Q3 Operating Profit 47.4 Billion Won, Down 11% From Year Earlier